MedTrace Logo

Natural Killer (NK) Cell Transplantation for AML

NCT00187096 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2014-06-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.

Conditions

Interventions

DRUG

Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2

See Detailed Description section for additional details of treatment interventions.

PROCEDURE

Natural Killer Cell Infusion

See Detailed Description section for additional details of treatment interventions.

DEVICE

CliniMACS System

See Detailed Description section for additional details of treatment interventions.

Sponsors & Collaborators

Principal Investigators

  • Jeffrey E. Rubnitz, M.D. · St. Jude Children's Research Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2012-02-29
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187096 on ClinicalTrials.gov